Key result
Olanzapine monotherapy linked to ~8 kg weight gain and adverse metabolic changes in psychotic disorders.
Why the study?
The study evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders.
Does olanzapine monotherapy worsen metabolic parameters and cardiovascular risk factors in patients with psychotic disorders?
Cohort (n=253)
No
Does olanzapine monotherapy worsen metabolic parameters and cardiovascular risk factors in patients with psychotic disorders?
Olanzapine monotherapy in patients with psychotic disorders is associated with significant adverse metabolic changes, leading to suboptimal attainment of cardiovascular risk factor targets.
Answers are grounded in this paper and cite their sources.
May warrant metabolic monitoring with olanzapine; leaves open effects on cardiovascular events versus alternatives.
We evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders. This was a retrospective cohort study involving patients prescribed olanzapine and attending Sultan Qaboos University Hospital (Muscat, Oman). Patients were followed up retrospectively from March 2006 until April 2021. Cardiovascular treatment targets were evaluated as per the 2019 European Society of Cardiology guidelines. We enrolled 253 patients (mean age: 40±17 years). Olanzapine monotherapy was associated with increased body weight (+8 kg; 95% confidence interval (CI): 6–9; P < .001), body mass index (+3 kg/m 2 ; 95% CI: 2–4; P < .001), total cholesterol (+.4 mmol/L; 95% CI: .3–.5; P < .001), low-density lipoprotein cholesterol (LDL-C) (+.3 mmol/L; 95% CI: .1–.4; P < .001), fasting triglycerides (+.2 mmol/L; 95% CI: .1–.3; P<.001), fasting glucose (+.6 mmol/L; 95% CI: .4–.7; P< .001), HbA1c (+.3%; 95% CI: .2–.4; P < .001), systolic blood pressure (BP) (+9 mmHg; 95% CI: 6–12; P < .001) and diastolic BP (+4 mmHg; 95% CI: 2–6; P < .001) levels. Cardiovascular therapeutic goals were attained in 38% (n = 97), 61% (n = 154), 71% (n = 180), and 59% (n = 150) for LDL-C, non–high-density lipoprotein cholesterol, triglycerides, and BP, respectively. Olanzapine was associated with adverse metabolic changes. Therefore, many patients were not at their target cardiovascular treatment goals.
No takes yet. Share an insight, caveat, or question.
Al-Tobi et al. (2022) conducted a cohort in psychotic disorders (n=253). olanzapine was evaluated on body weight change (+8 kg, 95% CI 6-9, p=<.001). Olanzapine monotherapy in patients with psychotic disorders was associated with increased body weight and other adverse metabolic changes.
Synapse has enriched 10 related papers. Consider them for comparative context: